Prolonged survival and milder impairment of motor function in the SOD1 ALS mouse model devoid of fibroblast growth factor 2

Neurobiology of Disease

Volumn 47, Issue 2, 2012, Pages 248-257

  Thau, Nadine ^a,b   Jungnickel, Julia ^a   Knippenberg, Sarah ^a,b   Ratzka, Andreas ^a   Dengler, Reinhard ^a,b   Petri, Susanne ^a,b   Grothe, Claudia ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Ciliary neurotrophic factor; Fibroblast growth factor 2; Glial derived neurotrophic factor; Neurodegenerative disease; Neurotrophic factors

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROTROPHIC FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; MALE; MOTONEURON; MOTOR PERFORMANCE; MOTOR SYSTEM; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SOD1 GENE; SPINAL CORD; SURVIVAL; UPREGULATION;

AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOTOR SKILLS; PSYCHOMOTOR PERFORMANCE; SUPEROXIDE DISMUTASE; SURVIVAL RATE;

EID: 84861667915     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.04.008     Document Type: Article

References (71)

1. Acsadi G., et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum. Gene Ther. 2002, 13:1047-1059.
2. Albrecht P.J., et al. Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production. Neurobiol. Dis. 2003, 13:89-101.
3. Alexander G.M., et al. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res. Mol. Brain Res. 2004, 130:7-15.
4. Almer G., et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 2001, 49:176-185.
5. Aquilonius S.M., et al. Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography. J. Neural Transm. Gen. Sect. 1992, 89:111-122.
6. Bruijn L.I., et al. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004, 27:723-749.
7. Cassina P., et al. Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J. Neurochem. 2005, 93:38-46.
8. Chen L., et al. Growth hormone, insulin-like growth factor I, and motoneuron size. J. Neurobiol. 1997, 32:202-212.
9. Clarke P.G., Oppenheim R.W. Neuron death in vertebrate development: in vitro methods. Methods Cell Biol. 1995, 46:277-321.
10. Cleveland D.W. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 1999, 24:515-520.
11. Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001, 2:806-819.
12. Coggeshall R.E., et al. An empirical method for converting nucleolar counts to neuronal numbers. J. Neurosci. Methods 1984, 12:125-132.
13. Dono R., et al. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J. 1998, 17:4213-4225.
14. Ekestern E. Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener. Dis. 2004, 1:88-100.
15. Federici T., Boulis N.M. Gene-based treatment of motor neuron diseases. Muscle Nerve 2006, 33:302-323.
16. Giess R., et al. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am. J. Hum. Genet. 2002, 70:1277-1286.
17. Goddard D.R., et al. Fibroblast growth factor-2 induces astroglial and microglial reactivity in vivo. J. Anat. 2002, 200:57-67.
18. Gonzalez A.M., et al. A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain. Brain Res. 1995, 701:201-226.
19. Grothe C., Unsicker K. Basic fibroblast growth factor in the hypoglossal system: specific retrograde transport, trophic, and lesion-related responses. J. Neurosci. Res. 1992, 32:317-328.
20. Grothe C., Wewetzer K. Fibroblast growth factor and its implications for developing and regenerating neurons. Int. J. Dev. Biol. 1996, 40:403-410.
21. Grothe C., et al. Effects of basic fibroblast growth factor on survival and choline acetyltransferase development of spinal cord neurons. Brain Res. Dev. Brain Res. 1991, 62:257-261.
22. Grothe C., et al. Physiological function and putative therapeutic impact of the FGF-2 system in peripheral nerve regeneration-lessons from in vivo studies in mice and rats. Brain Res. Rev. 2006, 51:293-299.
23. Grundstrom E., et al. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 2000, 11:1781-1783.
24. Gurney M.E., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
25. Henderson C.E., et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994, 266:1062-1064.
26. Henriques A., et al. Characterization of a novel SOD-1(G93A) transgenic mouse line with very decelerated disease development. PLoS One 2010, 5:e15445.
27. Hisaoka K., et al. Tricyclic antidepressant amitriptyline activates fibroblast growth factor receptor signaling in glial cells: involvement in glial cell line-derived neurotrophic factor production. J. Biol. Chem. 2011, 286:21118-21128.
28. Jiang Y.M., et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2005, 57:236-251.
29. Johansson A., et al. Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis. Neuroreport 2003, 14:1867-1869.
30. Jungnickel J., et al. Targeted disruption of the FGF-2 gene affects the response to peripheral nerve injury. Mol. Cell. Neurosci. 2004, 25:444-452.
31. Jungnickel J., et al. Regulation of neuronal death and calcitonin gene-related peptide by fibroblast growth factor-2 and FGFR3 after peripheral nerve injury: evidence from mouse mutants. Neuroscience 2005, 134:1343-1350.
32. Jungnickel J., et al. Faster nerve regeneration after sciatic nerve injury in mice over-expressing basic fibroblast growth factor. J. Neurobiol. 2006, 66:940-948.
33. Kerkhoff H., et al. Insulin-like and fibroblast growth factors in spinal cords, nerve roots and skeletal muscle of human controls and patients with amyotrophic lateral sclerosis. Acta Neuropathol. 1994, 87:411-421.
34. Klapdor K., et al. A low-cost method to analyse footprint patterns. J. Neurosci. Methods 1997, 75:49-54.
35. Knippenberg S., et al. Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). Behav. Brain Res. 2010, 213:82-87.
36. Knippenberg S., et al. Intraspinal injection of human umbilical cord blood-derived cells is neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis. 2011, 9:107-120.
37. Koshinaga M., et al. Altered acidic and basic fibroblast growth factor expression following spinal cord injury. Exp. Neurol. 1993, 120:32-48.
38. Kruchkova Y., et al. Basic fibroblast growth factor: a potential inhibitor of glutamine synthetase expression in injured neural tissue. J. Neurochem. 2001, 77:1641-1649.
39. Lenhard T., et al. Fibroblast growth factor-2 requires glial-cell-line-derived neurotrophic factor for exerting its neuroprotective actions on glutamate-lesioned hippocampal neurons. Mol. Cell. Neurosci. 2002, 20:181-197.
40. Li W., et al. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp. Neurol. 2007, 203:457-471.
41. Liao S., et al. Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease. Dev. Dyn. 2009, 238:249-264.
42. Liebetanz D., et al. Extensive exercise is not harmful in amyotrophic lateral sclerosis. Eur. J. Neurosci. 2004, 20:3115-3120.
43. Lin L.F., et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
44. Mayhew T.M., Momoh C.K. Proceedings: A histometric analysis of rat cervical cord: a study of motor horn morphology using the optical microscope. J. Anat. 1974, 118:371.
45. Miller R.G., et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996, 47:1329-1331.
46. Mitsumoto H., et al. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994, 265:1107-1110.
47. Muggeo V.M. Estimating regression models with unknown break-points. Stat. Med. 2003, 22:3055-3071.
48. Mulder D.W., et al. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 1986, 36:511-517.
49. Nagano I., et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2005, 235:61-68.
50. Oppenheim R.W., et al. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995, 373:344-346.
51. Oppenheim R.W., et al. Early regional variations in motoneuron numbers arise by differential proliferation in the chick embryo spinal cord. Dev. Biol. 1989, 133:468-474.
52. Penn R.D., et al. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 1997, 40:94-100.
53. Petri S., et al. Preserved expression of fibroblast growth factor (FGF)-2 and FGF receptor 1 in brain and spinal cord of amyotrophic lateral sclerosis patients. Histochem. Cell Biol. 2008, 131(4):509-519.
54. Pochon N.A., et al. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization. Eur. J. Neurosci. 1997, 9:463-471.
55. Przedborski S., et al. Recent advances in amyotrophic lateral sclerosis research. Curr. Neurol. Neurosci. Rep. 2003, 3:70-77.
56. Ratzka A., et al. FGF-2 deficiency does not influence FGF ligand and receptor expression during development of the nigrostriatal system. PLoS One 2011, 6:e23564.
57. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
58. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001, 344:1688-1700.
59. Schiffer D., et al. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 1996, 139:27-33. (Suppl.).
60. Springer J.E., et al. cDNA sequence and differential mRNA regulation of two forms of glial cell line-derived neurotrophic factor in Schwann cells and rat skeletal muscle. Exp. Neurol. 1995, 131:47-52.
61. Suter-Crazzolara C., Unsicker K. GDNF mRNA levels are induced by FGF-2 in rat C6 glioblastoma cells. Brain Res. Mol. Brain Res. 1996, 41:175-182.
62. Teng Y.D., et al. Basic fibroblast growth factor increases long-term survival of spinal motor neurons and improves respiratory function after experimental spinal cord injury. J. Neurosci. 1999, 19:7037-7047.
63. Upton-Rice M.N., et al. Basic fibroblast growth factor does not prolong survival in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1999, 46:934.
64. Vercelli A., et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2008, 31:395-405.
65. Wang Y., et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci. 2007, 27:304-307.
66. Wong P.C., et al. The genetic and molecular mechanisms of motor neuron disease. Curr. Opin. Neurobiol. 1998, 8:791-799.
67. Yamamoto M., et al. Expression of glial cell line-derived growth factor mRNA in the spinal cord and muscle in amyotrophic lateral sclerosis. Neurosci. Lett. 1996, 204:117-120.
68. Yamamoto M., et al. Expression of GDNF and GDNFR-alpha mRNAs in muscles of patients with motor neuron diseases. Neurochem. Res. 1999, 24:785-790.
69. Yan Q., et al. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995, 373:341-344.
70. Zhou H.L., et al. Changes in glial cell line-derived neurotrophic factor expression in the rostral and caudal stumps of the transected adult rat spinal cord. Neurochem. Res. 2008, 33:927-937.
71. Zurn A.D., et al. Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurones. Neuroreport 1994, 6:113-118.